Poolbeg Pharma PLC Board Appointment (4071A)
May 24 2023 - 2:00AM
UK Regulatory
TIDMPOLB
RNS Number : 4071A
Poolbeg Pharma PLC
24 May 2023
Poolbeg Pharma plc
Board Appointment
24 May 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg'
or the 'Company'), a leading biopharmaceutical company focusing on
infectious and prevalent diseases with a high unmet medical need,
announces the appointment of Brendan Buckley as an Independent
Non-Executive Director of the Company with immediate effect.
Brendan will also replace Cathal Friel as a member of the
Remuneration Committee.
Professor Buckley is the former Chief Medical Officer of ICON
plc, a medical graduate of University College Cork and a doctoral
graduate in Biochemistry in the Faculty of Medicine at Oxford
University. Prof Buckley has advised Poolbeg since inception and
has deep experience in metabolic diseases including over 40 years'
experience in clinical practice as a Consultant Physician in
endocrinology, diabetes and in academic clinical pharmacology.
Brendan was a member of the Board of Directors of the Irish
Medicines Board (now the Health Products Regulatory Authority),
chairing its statutory Advisory Committee for Human Medicines. He
was also a member of the European Medicines Agency Committee for
Orphan Medicinal Products (COMP) and of the European Medicines
Agency Scientific Advisory Committee on diabetes and metabolism.
Brendan has published over 150 scientific papers, mainly on
metabolic disease, as well as the recent key opinion-leading book
'Re-Engineering Clinical Trials'.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said : "We are
delighted to have Brendan join the Board of Directors. His
significant contribution to Poolbeg during his role as a member of
the Scientific Advisory Board, and his considerable industry
experience will be of tremendous benefit as we continue to pursue
our goal of becoming a one-stop-shop for pharma and biotechs
seeking products to in-license ."
Brendan Buckley, Non-Executive Director of Poolbeg Pharma, said:
" I am honoured to be joining the Board at this exciting time of
the Company's development. Poolbeg has a unique model and pipeline
and I look forward to working alongside such a strong Management
Team targeting a number of growing markets."
Regulatory Disclosures
The following disclosures are required under Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Mr Brendan Mary Buckley, aged 73, has held the following
directorships and/or partnerships in the past five years:
Current directorships:
-- hVIVO plc
-- FIGHTING BLINDNESS
-- DS BIOPHARMA LIMITED
-- Afimmune Limited
-- Open Orphan DAC
-- Imutex Ltd
Past directorships:
-- BREAKTHROUGH CANCER RESEARCH
-- Alliance for Clinical Research Excellence and Safety Inc.
Mr Buckley has a beneficial interest in 2,631,474 ordinary
shares of the Company representing approximately 0.5 per cent. of
the total voting rights.
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
finnCap Ltd (Nominated Adviser &
Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative
medicines to address the unmet need in infectious and other
prevalent diseases. Poolbeg has a disciplined portfolio approach to
mitigate risk, accelerate drug development, and enhance investor
returns. The Company simultaneously advances multiple programmes in
cost-effective clinical trials, rapidly generating early human
safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline.
Poolbeg also uses AI to interrogate human challenge trial data sets
to quickly identify new targets and drugs, and in-license near or
in the clinic medicines, leading to faster development and greater
commercial appeal.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025. Through opportunistic identification of assets
which complement Poolbeg's existing pipeline, the Company is
progressing programmes in oncology and metabolic syndromes; adding
disease areas with significant addressable markets.
With its initial assets from hVIVO plc (formerly Open Orphan
plc), an industry leading infectious disease and human challenge
trials business, Poolbeg has access to knowledge, experience, and
clinical data from over 20 years of human challenge trials. The
Company is using these insights to acquire new assets as well as
reposition clinical stage products, reducing spend and risk.
Amongst its portfolio of exciting assets, Poolbeg has a small
molecule immunomodulator for severe influenza and other acute
inflammatory conditions (POLB 001) which produces a highly
significant reduction in p38 MAP kinase driven cytokines in a
clinical setting; a first-in-class, intranasally administered
RNA-based immunotherapy for respiratory virus infections (POLB
002); and a vaccine candidate for Melioidosis (POLB 003). The
Company is also developing two O ral Delivery Programmes and is
progressing two A rtificial I ntelligence (AI) P rogrammes to add
promising new assets to its pipeline.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABLGDUIBDDGXX
(END) Dow Jones Newswires
May 24, 2023 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Apr 2023 to Apr 2024